pembrolizumab
merck
['melanoma', 'agent', 'pembro']
data dive from #esmo22: swog-s1801, a phase 2 study of adjuvant vs neoadjuvant pembrolizumab for resected stage iii-iv melanoma showed single-agent neoadjuvant pembrolizumab to have significantly higher efs compared to adjuvant pembrolizumab (cox hr 0.59, 95% ci: 0.50-0.86) 